CJC-1295 without DAC
/ Tetrasubstituted human GHRH(1-29) analog (D-Ala2, Gln8, Ala15, Leu27)ALIAS · Modified GRF 1-29 · Mod-GRF 1-29 · CJC-1295 (No DAC) · Tetrasubstituted GHRH(1-29)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. The 'no DAC' form is a tetrasubstituted GHRH(1-29) analog (D-Ala2, Gln8, Ala15, Leu27) without the DAC albumin-binding linker, giving a half-life of roughly 30 minutes — comparable to other short-acting GHRH analogs. No formal Phase 2 or Phase 3 trials.
The four amino-acid substitutions stabilise the molecule against proteolytic cleavage (notably DPP-IV at the N-terminus and trypsin at internal sites) but do not extend the half-life beyond what native GHRH analogs achieve. Receptor binding and signalling at the somatotrope GHRH receptor are pharmacologically similar to native GHRH and to sermorelin.
None. No Phase 1 or later trials specifically of CJC-1295 without DAC. Inference from sermorelin and tesamorelin (related GHRH analogs) is the closest available proxy but is not a substitute for direct human data.
No formal human safety database. Class-level GHRH analog safety expectations apply (injection-site reactions, flushing, theoretical IGF-1 elevation with chronic use).
Regulatory status
- FDA status:
- Not FDA-approved
Vendor marketing routinely conflates this molecule with the long-acting CJC-1295 with DAC. They are different compounds with different pharmacokinetics — the DAC version has Phase 1 data; the no-DAC version does not.